Table 4.
Redirecting T cell antigen specificity by knocking in transgenic TCRs (tTCR) into the TRAC locus.
| TCR/CAR | Antigen | Target gene |
TRAC KI | Enhanced tTCR expression |
In vitro |
In vivo |
Ref | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRAC | TRBC | IFN-γ | TNF-α | IL-2 | Cytotoxicity | Model | Tumor | |||||
| TCR | MLNA | Y | Y | Y | Y | [71] | ||||||
| HER2/Neu | Y | Y | Y | Y | [71] | |||||||
| BOB | Y | Y | [29] | |||||||||
| HA-1 | Y | Y | Y | + | + | Multiple myeloma | D | [29] | ||||
| MPO | Y | Y | Y | = | = | Myeloid leukeumia | = | [28] | ||||
| PRAME | Y | Y | [29] | |||||||||
| CMV | Y | Y | [29] | |||||||||
| CMV | Y | Y | Y | =/+ | = | = | [71] | |||||
| CAR | CD19 | Y | Y | Y | Leukemia | D | [30] | |||||
+, increased production; =, equal production; D, tumor outgrowth delayed; Y, yes. Blank indicates not reported.